| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_562e4af016953c0a80e09960559ed0d2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0695
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_443663c6fbf02e584c9dd7d3480cb574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab6650961f4a6d89dcf525770a90ee38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3843871156a1cf059194100dad7a95a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d138cceb581695cb48150691ead79a5a |
| publicationDate |
2015-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015168255-A1 |
| titleOfInvention |
Methods and compositions for targeting cancer stem cells |
| abstract |
Aspects of the disclosure relate to methods that involve activating the Protein Kinase A (PKA) pathway to induce cancer stem cells (CSCs) to undergo a mesenchymal to epithelial transition. Methods provided herein are useful, in some embodiments, because they render CSCs amenable to treatment with conventional cancer therapies. In some embodiments, methods are provided that involve assaying PKA pathway activity to identify compounds that selectively target CSCs. |
| priorityDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |